# RayzeBio

develops SSTR2-targeted radiopharmaceutical therapies for gastroenteropancreatic neuroendocrine tumors and operates a dedicated Indianapolis hub for end-to-end manufacturing and on-demand delivery of its clinical-stage RPT candidates.

Source: https://en.bioecon.ru/companies/rayzebio/
Updated: 2026-07-03

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | Raised at least $418 million in equity capital by 2022 and planned a $173 million investment in 2026 to expand manufacturing operations in Indiana. | https://rayzebio.com/rayzebio-advances-ryz101-a-targeted-radiopharmaceutical-delivering-actinium-225-into-clinical-development-for-two-cancer-indications/, https://trial.medpath.com/news/rayzebio-announces-173-million-investment-to-expand-radiopharmaceutical-manufacturing-in-indiana |
| Capacity | Designed to manufacture tens of thousands of doses annually when operating at full capacity. | https://rayzebio.com/what-we-do/manufacturing/, https://trial.medpath.com/news/rayzebio-announces-173-million-investment-to-expand-radiopharmaceutical-manufacturing-in-indiana, https://www.bms.com/life-and-science/insights/new-rayzebio-hub-accelerates-next-gen-cancer-therapies.html, https://www.ibj.com/articles/drug-manufacturing-facility-offers-new-hope-in-cancer-fight |
| Production site | Existing 77,000-square-foot facility in Indianapolis, Indiana; plans for a new 450,000-square-foot facility in Boone County, Indiana. | https://rayzebio.com/what-we-do/manufacturing/, https://trial.medpath.com/news/rayzebio-announces-173-million-investment-to-expand-radiopharmaceutical-manufacturing-in-indiana, https://www.ibj.com/articles/drug-manufacturing-facility-offers-new-hope-in-cancer-fight |
| Headcount | Approximately 100 employees as of July 2025, with plans to create up to 100 additional jobs by the end of 2029. | https://trial.medpath.com/news/rayzebio-announces-173-million-investment-to-expand-radiopharmaceutical-manufacturing-in-indiana, https://www.ibj.com/articles/drug-manufacturing-facility-offers-new-hope-in-cancer-fight |
| Revenue | $380 million (2024), $250 million (2023), $90 million (2022), $120 million (2021), $65 million (2020). | https://www.privco.com/company/rayzebio, https://www.sec.gov/Archives/edgar/data/1825367/000162828023038595/ryzb-20230930.htm |

Independent sources: bms.com, ibj.com, privco.com, sec.gov, trial.medpath.com

## Technologies

- [Radiopharmaceuticals & theranostics](https://en.bioecon.ru/technology/radiopharmaceuticals-theranostics/)